2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
F Pacini, D Fuhrer, R Elisei… - European Thyroid …, 2022 - etj.bioscientifica.com
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid
cancer (DTC) should be implemented in line with patients' risk stratification. Although …
cancer (DTC) should be implemented in line with patients' risk stratification. Although …
[HTML][HTML] Tall cell variant of papillary thyroid carcinoma: current evidence on clinicopathologic features and molecular biology
X Wang, W Cheng, C Liu, J Li - Oncotarget, 2016 - ncbi.nlm.nih.gov
Tall cell variant (TCV) of papillary thyroid carcinoma (PTC) has been recognized for the past
few decades as an entity showing aggressive biological behavior; however, there is …
few decades as an entity showing aggressive biological behavior; however, there is …
Differentiated thyroid cancer, from active surveillance to advanced therapy: toward a personalized medicine
A Matrone, MC Campopiano, A Nervo… - Frontiers in …, 2020 - frontiersin.org
Differentiated thyroid cancer (DTC) is the most frequent endocrine malignancy and
represents the most rapidly increasing cancer diagnosis worldwide. In the last 20 years, this …
represents the most rapidly increasing cancer diagnosis worldwide. In the last 20 years, this …
Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma
Importance While well-differentiated papillary thyroid carcinoma (WDPTC) outcomes have
been well characterized, the prognostic implications of more aggressive variants are far less …
been well characterized, the prognostic implications of more aggressive variants are far less …
Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis
Background: Tall cell variant (TCV) and diffuse sclerosing variant (DSV) of papillary thyroid
cancer are aggressive subtypes, for which tumors≤ 1 cm have not been exclusively studied …
cancer are aggressive subtypes, for which tumors≤ 1 cm have not been exclusively studied …
Radioiodine therapy in the different stages of differentiated thyroid cancer
L Valerio, F Maino, MG Castagna, F Pacini - Best Practice & Research …, 2023 - Elsevier
Differentiated thyroid cancer is the most frequent type of thyroid cancer with an increasing
incidence in the last decades. The initial management is represented by surgical treatment …
incidence in the last decades. The initial management is represented by surgical treatment …
[HTML][HTML] A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis
Z Liu, W Zeng, T Chen, Y Guo, C Zhang, C Liu… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Papillary thyroid cancer (PTC) accounts for 80–90% of all thyroid malignancies. The tall cell
variant (TCV) is a rare aggressive histotype of PTC. We performed a meta-analysis to …
variant (TCV) is a rare aggressive histotype of PTC. We performed a meta-analysis to …
A nomogram and risk classification system for predicting cancer-specific survival in tall cell variant of papillary thyroid cancer: a SEER-based study
X Wang, X Zheng, J Zhu, Z Li, T Wei - Journal of endocrinological …, 2023 - Springer
Background Tall cell variant (TCV) of papillary thyroid cancer (PTC) is the most common
aggressive subtype of PTC. The factors that affect survival of patients with TCV remain …
aggressive subtype of PTC. The factors that affect survival of patients with TCV remain …
[HTML][HTML] Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features
Background The tall cell variant of papillary thyroid carcinoma (TCVPTC) is more aggressive
than classic papillary thyroid carcinoma (PTC), but the percentage of tall cells needed to …
than classic papillary thyroid carcinoma (PTC), but the percentage of tall cells needed to …
Papillary thyroid carcinoma tall cell variant shares accumulation of mitochondria, mitochondrial DNA mutations, and loss of oxidative phosphorylation complex I …
O Tsybrovskyy, M De Luise, D de Biase… - The Journal of …, 2022 - Wiley Online Library
Papillary thyroid carcinoma tall cell variant (PTC‐TCV), a form of PTC regarded as an
aggressive subtype, shares several morphologic features with oncocytic tumors. Pathogenic …
aggressive subtype, shares several morphologic features with oncocytic tumors. Pathogenic …